Chronic Kidney Disease (CKD)

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure (AstraZeneca)

Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure Sponsor: CKD & HTN Indication: Alport Syndrome Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure (AstraZeneca) Read More »

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome (Enyo Pharma)

Protocol Name: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome Sponsor: Enyo Pharma Indication: Alport Syndrome Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome (Enyo Pharma) Read More »

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity

Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity Principal Investigator:Bernard Fischbach, MD Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Read More »

Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria

Protocol Name: Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria Sponsor: Mineralys Indication: Chronic Kidney Disease (CKD) Principal Investigator: Kim Rice, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

Phase 2 Study of Lorundrostat Alone or in Combination with Dapagliflozin in adults with HTN and CKD with Albuminuria Read More »